title: Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.
abstract: The term mastocytosis denotes a heterogenous group of disorders characterized by abnormal growth and accumulation of mast cells in one or more organs. Cutaneous and systemic variants of the disease have been described. Mast cell disorders have also been categorized according to other aspects, such as family history, age, course of disease, or presence of a concomitant myeloid neoplasm. However, so far, generally accepted disease criteria are missing. Recently, a number of diagnostic (disease-related) markers have been identified in mastocytosis research. These include the mast cell enzyme tryptase, CD2, and mast cell growth factor receptor c-kit (CD117). Several gain-of-function-mutations in the kinase domain of c-kit appear to occur in mastocytosis supporting the clonal (neoplastic) nature of the disease. Also, certain point mutations appear to be associated with distinct variants of mastocytosis, i.e. Asp-816-->Val with a subset of sporadic persistent (systemic) mastocytosis (mostly adults), and Gly-839-->Lys with (a subset of) typical pediatric (mostly cutaneous) mastocytosis. Another potential indicator of mast cell neoplasm is the T-/NK-cell-associated marker CD2. This antigen (LFA-2) is abnormally expressed on neoplastic mast cells in cases of systemic mastocytosis or mast cell leukemia, but not found on normal mast cells. The mast cell enzyme tryptase is increasingly used as a serum- and immunohistochemical marker to estimate the actual spread of disease (burden of neoplastic mast cells). The clinical significance of novel mastocytosis markers is currently under investigation. First results indicate that they may be useful to define reliable criteria for the delineation of the disease.
authors.affiliation: Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Valent
authors.forename: L
authors.initials: L
authors.lastname: Escribano
authors.forename: R M
authors.initials: RM
authors.lastname: Parwaresch
authors.forename: V
authors.initials: V
authors.lastname: Schemmel
authors.forename: L B
authors.initials: LB
authors.lastname: Schwartz
authors.forename: K
authors.initials: K
authors.lastname: Sotlar
authors.forename: W R
authors.initials: WR
authors.lastname: Sperr
authors.forename: H P
authors.initials: HP
authors.lastname: Horny
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D001854:Bone Marrow Cells / Q000473:pathology; D053818:Chymases; D006801:Humans; D007150:Immunohistochemistry; D008407:Mast Cells / Q000473:pathology; D008415:Mastocytosis / Q000235:genetics / Q000276:immunology / Q000473:pathology; D010641:Phenotype; D017354:Point Mutation; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D012697:Serine Endopeptidases / Q000097:blood; D009626:Terminology as Topic; D053802:Tryptases
chemical_list: D015703:Antigens, CD; D019009:Proto-Oncogene Proteins c-kit; D012697:Serine Endopeptidases; C083294:chymase 2; D053818:Chymases; D053802:Tryptases